Page 300 - Read Online
P. 300

Fung et al.                                                                                                                                                         Antivirals in hepatitis B hepatocellular carcinoma

           63.  Chong CC, Wong GL, Wong VW, Ip PC, Cheung YS, Wong J, Lee   survival. Hepatology 2003;37:429-42.
               KF, Lai PB, Chan HL. Antiviral therapy improves post-hepatectomy   79.  Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill
               survival in patients with hepatitis B virus-related hepatocellular   H, Lam YF, Lie AK, Lai CL, Kwong YL, Yuen MF. Hepatitis B
               carcinoma: a prospective-retrospective study. Aliment Pharmacol   reactivation in patients with previous hepatitis B virus exposure
               Ther 2015;41:199-208.                             undergoing rituximab-containing chemotherapy for lymphoma: a
           64.  Ke Y, Ma L, You XM, Huang SX, Liang YR, Xiang BD, Li   prospective study. J Clin Oncol 2014;32:3736-43.
               LQ, Zhong JH. Antiviral therapy for hepatitis B virus-related   80.  Seto WK. Hepatitis B virus reactivation during immunosuppressive
               hepatocellular carcinoma after radical hepatectomy. Cancer Biol Med   therapy: appropriate risk stratification. World J Hepatol 2015;7:825-
               2013;10:158-64.                                   30.
           65.  Huang S, Xia Y, Lei Z, Zou Q, Li J, Yang T, Wang K, Yan Z, Wan   81.  Lao XM, Wang D, Shi M, Liu G, Li S, Guo R, Yuan Y, Chen M,
               X, Shen F. Antiviral therapy inhibits viral reactivation and improves   Li J, Zhang Y, Lin X. Changes in hepatitis B virus DNA levels and
               survival after repeat hepatectomy for hepatitis B virus-related recurrent   liver function after transcatheter arterial chemoembolization of
               hepatocellular carcinoma. J Am Coll Surg 2017;224:283-93.e4.  hepatocellular carcinoma. Hepatol Res 2011;41:553-63.
           66.  Fung J. Managing hepatitis B: before and after liver transplantation.   82.  Xu X, Huang P, Tian H, Chen Y, Ge N, Tang W, Yang B, Xia J. Role
               Ind J Transpl 2011;5:77-80.                       of lamivudine with transarterial chemoembolization in the survival
           67.  Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in   of patients with hepatocellular carcinoma. J Gastroenterol Hepatol
               severe liver disease. World J Gastroenterol 2014;20:16053-61.  2014;29:1273-8.
           68.  Markowitz JS, Martin P, Conrad AJ, Markmann JF, Seu P, Yersiz H,   83.  Shao W, Zhang F, Cong N, Li J, Song J. The hepatitis B virus
               Goss JA, Schmidt P, Pakrasi A, Artinian L, Murray NG, Imagawa   reactivation after transarterial chemoembolization in Chinese
               DK, Holt C, Goldstein LI, Stribling R, Busuttil RW. Prophylaxis   hepatocellular carcinoma patients with low serum hepatitis B virus
               against hepatitis B recurrence following liver transplantation using   DNA level. Ther Clin Risk Manag 2015;11:1367-70.
               combination lamivudine and hepatitis B immune globulin. Hepatology   84.  Li X, Zhong X, Chen ZH, Wang TT, Ma XK, Xing YF, Wu DH, Dong
               1998;28:585-9.                                    M, Chen J, Ruan DY, Lin ZX, Wen JY, Wei L, Wu XY, Lin Q. Efficacy
           69.  Shouval D, Samuel D. Hepatitis B immune globulin to prevent   of prophylactic entecavir for hepatitis B virus-related hepatocellular
               hepatitis B virus graft reinfection following liver transplantation: a   carcinoma receiving transcatheter arterial chemoembolization. Asian
               concise review. Hepatology 2000;32:1189-95.       Pac J Cancer Prev 2015;16:8665-70.
           70.  Gane EJ, Angus PW, Strasser S, Crawford DH, Ring J, Jeffrey   85.  Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi
               GP, McCaughan GW. Lamivudine plus low-dose hepatitis B   J, Tajiri N, Yamasaki S, Koga H, Torimura T, Kumashiro R, Sata M.
               immunoglobulin to prevent recurrent hepatitis B following liver   Prophylactic lamivudine administration prevents exacerbation of
               transplantation. Gastroenterology 2007;132:931-7.  liver damage in HBe antigen positive patients with hepatocellular
           71.  Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E.   carcinoma undergoing transhepatic arterial infusion chemotherapy.
               A randomized study of adefovir dipivoxil in place of HBIG in   Am J Gastroenterol 2004;99:2369-75.
               combination with lamivudine as post-liver transplantation hepatitis B   86.  Li X, Zhong X, Chen ZH, Xing YF, Wu DH, Chen J, Ma XK, Lin
               prophylaxis. Hepatology 2008;48:1460-6.           Q, Wen JY, Wei L, Wang TT, Ruan DY, Lin ZX, Wu XY, Dong M.
           72.  Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC,   Hepatitis B virus DNA negativity acts as a favorable prognostic
               Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir   factor in hepatocellular carcinoma patients. Asian Pac J Cancer Prev
               monotherapy is effective in suppressing hepatitis B virus after liver   2014;15:9635-41.
               transplantation. Gastroenterology 2011;141:1212-9.  87.  Dan JQ, Zhang YJ, Huang JT, Chen MS, Gao HJ, Peng ZW, Xu L,
           73.  Fung J, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan   Lau WY. Hepatitis B virus reactivation after radiofrequency ablation
               AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/  or hepatic resection for HBV-related small hepatocellular carcinoma:
               nucleotide analogs without hepatitis B immune globulin after liver   a retrospective study. Eur J Surg Oncol 2013;39:865-72.
               transplantation for hepatitis B. Am J Gastroenterol 2013;108:942-8.  88.  Sohn W, Paik YH, Lee MW, Rhim H, Lim HK, Cho JY, Gwak GY,
           74.  Fung J, Wong T, Chok K, Chan A, Cheung TT, Dai J, Sin SL, Ma KW,   Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Predisposing factors
               Ng K, Ng K, Seto WK, Lai CL, Fung Yuen M, Lo CM. Long term   for recurrence of HBV-related small hepatocellular carcinoma
               outcomes of entecavir monotherapy for chronic hepatitis B after liver   after percutaneous radiofrequency ablation. Scand J Gastroenterol
               transplantation: results up to 8 years. Hepatology 2017;66:1036-44.  2014;49:373-80.
           75.  Fung J, Wong T, Chok K, Chan A, Sin SL, Cheung TT, Dai WC, Ng K,   89.  Sohn W, Kang TW, Choi SK, Jung SH, Lee MW, Lim HK, Cho JY,
               Ng K, Man K, Seto WK, Lai CL, Yuen MF, Lo CM. Oral nucleos(t)  Shim SG, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW,
               ide analogs alone after liver transplantation in chronic hepatitis B with   Rhim H, Paik YH. Effect of oral antiviral treatment on long-term
               preexisting rt204 mutation. Transplantation 2017;101:2391-8.  outcomes of radiofrequency ablation therapy for hepatitis B virus-
           76.  Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown R,   related hepatocellular carcinoma. Oncotarget 2016;7:47794-807.
               Cameron A, Ghobrial M, Kam I, Busuttil R, Saab S, Holt C, Emond J,   90.  Lee TY, Lin JT, Zeng YS, Chen YJ, Wu MS, Wu CY. Association
               Stiles J, Lukose T, Chang M, Klintmalm G. Liver transplantation for   between nucleos(t)ide analog and tumor recurrence in hepatitis B
               hepatitis B liver disease and concomitant hepatocellular carcinoma in   virus-related hepatocellular carcinoma after radiofrequency ablation.
               the United States with hepatitis B immunoglobulin and nucleoside/  Hepatology 2016;63:1517-27.
               nucleotide analogues. Liver Transpl 2013;19:1020-9.  91.  Yoo SH, Jang JW, Kwon JH, Jung SM, Jang B, Choi JY. Preemptive
           77.  Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, Roche B,   antiviral therapy with entecavir can reduce acute deterioration of
               Fallot G, Ferrari TC, Guettier C, Dussaix E, Castaing D, Brechot C,   hepatic function following transarterial chemoembolization. Clin Mol
               Samuel D. Hepatocellular carcinoma is associated with an increased   Hepatol 2016;22:458-65.
               risk of hepatitis B virus recurrence after liver transplantation.   92.  Hann HW, Coben R, Brown D, Needleman L, Rosato E, Min A, Hann
               Gastroenterology 2008;134:1890-9; quiz 2155.      RS, Park KB, Dunn S, DiMarino AJ. A long-term study of the effects
           78.  Llovet JM, Bruix J. Systematic review of randomized trials for   of antiviral therapy on survival of patients with HBV-associated
               unresectable hepatocellular carcinoma: chemoembolization improves   hepatocellular carcinoma (HCC) following local tumor ablation.

            292                                                                                                      Hepatoma Research ¦ Volume 3 ¦ November 27, 2017
   295   296   297   298   299   300   301   302   303   304   305